Multiple Myeloma

Triplet Therapy for Relapsed or Refractory Multiple Myeloma May Improve Clinical Outcomes

By

Megan Garlapow, PhD

Publish Date April 25, 2019

Pomalidomide, cyclophosphamide, and dexamethasone triplet therapy for relapsed/refractory multiple myeloma had an overall response rate of 76%.

Indirect Measures Demonstrated High Level of Adherence to Oral Immunomodulatory Therapy for Multiple Myeloma

By

Susan Moench, PhD, PA-C

Publish Date April 15, 2019

Using separate indirect medication adherence measures, researchers determined adherence rates for patients with MM treated with oral immunomodulatory therapy.

Cardiovascular, Thromboembolic Mortality Risk Factors in Multiple Myeloma

By

Megan Garlapow, PhD

Publish Date April 8, 2019

An analysis of SEER data identified the risk for these cardiovascular events and the common related causes of death among patients with MM.

Uncertainty Common in Primary Family Caregivers of Patients With Multiple Myeloma

By

Susan Moench, PhD, PA-C

Publish Date March 7, 2019

Researchers find trends among physical and emotional challenges associated with being the primary family caregiver of a patient with multiple myeloma.

Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma

By

Christina Bennett, MS

Publish Date February 11, 2019

Takeda will work with Memorial Sloan Kettering Cancer Center to develop CAR-T therapies for multiple myeloma.